...
首页> 外文期刊>Current pharmaceutical design >Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.
【24h】

Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy.

机译:放射性药物的生物载体分子,用于分子癌症成像和靶向癌症治疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Many tumors express one or more proteins that are either absent or hardly present in normal tissues, and which can be targeted by radiopharmaceuticals for either visualization of tumor cells or for targeted therapy. Radiopharmaceuticals can consist of a radionuclide and a carrier molecule that interacts with the tumor target and as such guides the attached radionuclide to the right spot. Radiopharmaceuticals hold great promise for the future of oncology by providing early, precise diagnosis and better, personalized treatment. Most advanced developments with marketed products are based on whole antibodies or antibody fragments as carrier molecules. However, a substantial number of (pre)clinical studies indicate that radiopharmaceuticals based on other carrier molecules, such as peptides, nonimmunoglobulin scaffolds, or nucleic acids may be valuable alternatives. In this review, we discuss the biological molecules that can deliver radionuclide payloads to tumor cells in terms of their structure, the selection procedure, their (pre)clinical status, and advantages or obstacles to their use in a radiopharmaceutical design. We also consider the plethora of molecular targets existing on cancer cells that can be targeted by radiopharmaceuticals, as well as how to select a radionuclide for a given diagnostic or therapeutic product.
机译:许多肿瘤表达一种或多种蛋白质,这些蛋白质在正常组织中不存在或几乎不存在,并且可以被放射性药物靶向以用于肿瘤细胞的可视化或靶向治疗。放射性药物可以由放射性核素和与肿瘤靶标相互作用的载体分子组成,从而将附着的放射性核素引导至正确的位置。放射性药物通过提供早期,精确的诊断和更好的个性化治疗,对肿瘤学的未来具有广阔的前景。市售产品的最先进开发基于完整抗体或抗体片段作为载体分子。然而,大量的(临床前)研究表明,基于其他载体分子(例如肽,非免疫球蛋白支架或核酸)的放射性药物可能是有价值的替代物。在这篇综述中,我们讨论了可以将放射性核素有效载荷传递给肿瘤细胞的生物分子,包括其结构,选择程序,其(临床前)临床状况以及其在放射性药物设计中的优势或障碍。我们还考虑了放射性药物可以靶向癌细胞上存在的众多分子靶标,以及如何为给定的诊断或治疗产品选择放射性核素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号